CCG
XBI icon

Chatham Capital Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Chatham Capital Group’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$499K Hold
3,153
– – 0.06% 166
2026
Q1 		$403K Hold
3,153
– – 0.06% 170
2025
Q4 		$384K Sell
3,153
-1,260
-29% -$144K 0.05% 169
2025
Q3 		$442K Hold
4,413
– – 0.06% 161
2025
Q2 		$366K Sell
4,413
-560
-11% -$44.7K 0.06% 172
2025
Q1 		$403K Sell
4,973
-105
-2% -$9.38K 0.07% 160
2024
Q4 		$457K Sell
5,078
-1,300
-20% -$126K 0.08% 153
2024
Q3 		$630K Buy
6,378
+150
+2% +$14.7K 0.1% 140
2024
Q2 		$577K Sell
6,228
-80
-1% -$7.17K 0.1% 139
2024
Q1 		$599K Hold
6,308
– – 0.11% 139
2023
Q4 		$563K Sell
6,308
-90
-1% -$6.68K 0.11% 143
2023
Q3 		$467K Hold
6,398
– – 0.1% 146
2023
Q2 		$532K Hold
6,398
– – 0.11% 145
2023
Q1 		$488K Sell
6,398
-125
-2% -$10.4K 0.11% 148
2022
Q4 		$541K Sell
6,523
-50
-0.8% -$4.05K 0.13% 137
2022
Q3 		$521K Buy
6,573
+2
+0% +$169 0.13% 134
2022
Q2 		$488K Sell
6,571
-180
-3% -$13.5K 0.11% 139
2022
Q1 		$607K Sell
6,751
-2,860
-30% -$264K 0.12% 135
2021
Q4 		$1.08M Sell
9,611
-250
-3% -$30.2K 0.19% 112
2021
Q3 		$1.24M Sell
9,861
-100
-1% -$12.9K 0.24% 96
2021
Q2 		$1.35M Buy
9,961
+2
+0% +$263 0.26% 93
2021
Q1 		$1.35M Buy
9,959
+33
+0.3% +$4.94K 0.28% 90
2020
Q4 		$1.4M Buy
9,926
+118
+1% +$15.1K 0.31% 84
2020
Q3 		$1.09M Buy
9,808
+58
+0.6% +$6.5K 0.27% 85
2020
Q2 		$1.09M Buy
9,750
+394
+4% +$38.8K 0.28% 82
2020
Q1 		$725K Sell
9,356
-44,759
-83% -$3.96M 0.21% 104
2019
Q4 		$5.15M Sell
54,115
-5,670
-9% -$490K 1.27% 24
2019
Q3 		$4.56M Sell
59,785
-2,025
-3% -$168K 1.16% 26
2019
Q2 		$5.42M Buy
61,810
+705
+1% +$60.1K 1.37% 23
2019
Q1 		$5.53M Sell
61,105
-2,340
-4% -$199K 1.42% 23
2018
Q4 		$4.55M Sell
63,445
-10,040
-14% -$809K 1.26% 24
2018
Q3 		$7.04M Buy
73,485
+1,450
+2% +$141K 1.78% 18
2018
Q2 		$6.86M Hold
72,035
– – 1.8% 20
2018
Q1 		$6.32M Buy
72,035
+1,265
+2% +$115K 1.7% 19
2017
Q4 		$6.01M Sell
70,770
-1,600
-2% -$134K 1.65% 21
2017
Q3 		$6.26M Buy
72,370
+9,680
+15% +$776K 1.77% 17
2017
Q2 		$4.84M Buy
62,690
+1,450
+2% +$103K 1.34% 24
2017
Q1 		$4.24M Buy
61,240
+10,230
+20% +$687K 1.19% 26
2016
Q4 		$3.02M Buy
51,010
+11,650
+30% +$719K 0.88% 34
2016
Q3 		$2.61M Buy
+39,360
New +$2.43M 0.82% 35
2016
Q1 		– Sell
-2,915
Closed -$205K – 140
2015
Q4 		$205K Buy
+2,915
New +$199K 0.07% 138
2015
Q3 		– Sell
-2,415
Closed -$203K – 152
2015
Q2 		$203K Buy
+2,415
New +$188K 0.06% 150

Other funds holding XBI

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
AAS
Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return
EWM
Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return
LHWM
Lake Hills Wealth Management Austin, Texas $220M AUM 39.11% 1-Year Est. Return
MWA
MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return
PI
Parkside Investments Deerfield, Illinois $902M AUM 32.45% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
MAM
Marotta Asset Management Charlottesville, Virginia $601M AUM 21.35% 1-Year Est. Return

Chatham Capital Group's XBI Position: Q2 2026 in Review

Chatham Capital Group held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 3,153 shares worth $499K. The position accounts for 0.06% of the portfolio, ranked #166.

Chatham Capital Group first reported a position in XBI in Q2 2015 and has held it in 42 quarters since. The position peaked at $7.04M in Q3 2018. 131 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Chatham Capital Group held 3,153 shares of State Street SPDR S&P Biotech ETF worth $499K as of Q2 2026.
  • Chatham Capital Group left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
  • State Street SPDR S&P Biotech ETF made up 0.06% of Chatham Capital Group's portfolio in Q2 2026, its #166 holding.
  • Chatham Capital Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and has held it in 42 quarters since.
  • Chatham Capital Group's State Street SPDR S&P Biotech ETF position peaked at $7.04M in Q3 2018.
  • 131 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Chatham Capital Group's 13F filing for Q2 2026, filed 13 Jul 2026.